Lexaria Bioscience Corp (LEXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 08/31
| 02-2022 | 11-2021 | 08-2021 | 05-2021 | 02-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -3,452 | -2,004 | -4,186 | -2,862 | -295 |
| Depreciation Amortization | 54 | 28 | 148 | 84 | 56 |
| Accounts receivable | -164 | -119 | 190 | -1 | -69 |
| Other Working Capital | -57 | 49 | 64 | 68 | -103 |
| Other Operating Activity | 1,176 | 879 | -204 | -167 | -1,309 |
| Operating Cash Flow | $-2,444 | $-1,166 | $-3,990 | $-2,878 | $-1,721 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -42 | -42 | 273 | 273 | 273 |
| Purchase Sale Intangibles | -50 | -16 | -80 | -80 | -9 |
| Other Investing Activity | -50 | -16 | -80 | -80 | -9 |
| Investing Cash Flow | $-93 | $-58 | $194 | $194 | $265 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | -23 | N/A | N/A |
| Debt Repayment | -22 | -11 | -44 | -33 | -22 |
| Common Stock Issued | N/A | N/A | 13,487 | 9,472 | 9,472 |
| Other Financing Activity | 0 | 0 | 0 | -23 | -23 |
| Financing Cash Flow | $-22 | $-11 | $13,420 | $9,415 | $9,426 |
| Beginning Cash Position | 10,918 | 10,918 | 1,294 | 1,294 | 1,294 |
| End Cash Position | 8,359 | 9,682 | 10,918 | 8,109 | 9,347 |
| Net Cash Flow | $-2,558 | $-1,236 | $9,624 | $6,815 | $8,053 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,444 | -1,166 | -3,990 | -2,878 | -1,721 |
| Capital Expenditure | -42 | -42 | N/A | N/A | N/A |
| Free Cash Flow | -2,486 | -1,209 | -3,990 | -2,878 | -1,721 |